NEW YORK, March 2 - Tartu, Estonia may seem an unlikely launch point for a global assault on the SNP chip market. But Asper Biotech, a small Estonian microarray startup, hopes to leverage its unique chip-based sequencing technology to do just that. 

"Asper's edge is that manufacturing on a chip and reagent costs are way lower," than other SNP sequencing methods, said Kalev Kask, director of Asper's US office. "Our cost is definitely below 50 cents a SNP right now."  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.